Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 31, 2022
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that the Company’s shareholders are invited to participate in the Combined General Meeting, to be held on Tuesday, May 31, 2022, at 2 pm CET in the premises of the hotel L’Arcade, located at 9 rue de l’Arcade, 75008, Paris.
The prior notice of meeting comprising the agenda and draft resolutions was published in the BALO (Bulletin des Annonces Légales Obligatoires) on April 25, 2022, and the convening notice shall be published in a newspaper empowered to publish legal notices on May 13, 2022.
The documents provided for in articles R.22-10-23 of the French Commercial Code, are available for consultation on the company’s website mentioned below as of today, the twenty-first day prior to the General Meeting: www.sensorion.com.
In accordance with articles R.225-83 of the French Commercial Code, documents are available for the shareholders from the time the meeting is convened. In accordance with applicable regulations:
- any registered shareholders can, until the fifth day (inclusive) before the Meeting, request from the Company to receive these documents, including at their request, by way of an electronic mail. For holders of bearer shares, the exercise of this right is subject to the presentation of a certificate of attendance in the bearer share accounts kept by the empowered intermediary;
- any shareholder may consult these documents at the registered office of the Company.
* * *
For any questions relating to the Annual General Meeting of May 31, 2022, shareholders are invited to send an email to email@example.com.
In the changing context of the COVID-19 epidemic, and the measures adopted to prevent it from spreading, the conditions for holding and taking part in this Combined Shareholders’ General Meeting may evolve depending on the health, regulatory and legal requirements in place. In general, shareholders are invited to regularly consult the section dedicated to the General Meeting on the Company's website www.sensorion.com.
Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need.
Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates. Its portfolio combines both small molecule programs and a preclinical portfolio of inner ear gene therapies.
Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 Proof of Concept study of SENS-401 clinical study in cisplatin-induced ototoxicity (CIO) and, with partner Cochlear Limited, a study of SENS-401 in patients scheduled for cochlear implantation.
Sensorion has entered into a broad strategic collaboration with Institut Pasteur focused on the genetics of hearing. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness including deafness caused by a mutation of the gene encoding for Otoferlin, and hearing loss related to mutation in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses.
This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking
statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2021 full year financial report published on April 28, 2022, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.
Head of Investor Relations & Communication
+ 33 6 72 18 00 22
International Media Relations
Mary-Jane Elliott/Jessica Hodgson
+ 44 7739 788014+44 7561 424788